CRISPR Therapeutics AG (CRSP) · Oct 19, 2026 · Exec change

CRISPR Therapeutics CFO change brings internal successor, not a clean break

CFO departure — Internal promotion; predecessor remains through November 30, 2026

CRISPR Therapeutics announces a CFO change as Raju Prasad departs and longtime finance executive Andrew Silver takes over, preserving continuity.

CRISPR Therapeutics is shifting from proving gene editing works to commercializing CASGEVY while funding a broad clinical pipeline; in the latest reported quarter, CASGEVY revenue reached $76 million and the company had advanced multiple in vivo programs into Phase 1. This makes finance continuity more important than a routine title change. The company is losing Raju Prasad, who had served as CFO since March 2023, but the filing says he will remain employed through a date on or before November 30, 2026 and that his resignation was not caused by a disagreement over operations, accounting, controls, or disclosures. 〔0〕 〔1〕 The successor is a continuity choice, not an outside reset. Andrew J. Silver has been with CRISPR since October 2018, served as SVP of Finance since January 2025, and has covered strategic finance, treasury, planning and analysis, accounting, tax, and financial operations. 〔2〕 That background should reduce near-term handoff risk as CASGEVY commercialization and the pipeline’s clinical milestones place greater demands on forecasting, reporting, and capital planning. The employment package is standard senior-executive retention economics, with a somewhat meaningful change-in-control backstop. Silver receives a $515,000 salary, a 45% target bonus, and 25,000 restricted stock units vesting after two years. 〔3〕 The agreement also provides six months of notice for an involuntary departure, expanding to 12 months after a change in control, with acceleration of time-based equity subject to the agreement’s conditions. The main negative is the loss of an established CFO during an execution-heavy phase; the main offset is that the replacement is internal and the transition is partially overlapped. The filing does not indicate a financial restatement, control issue, strategic disagreement, or emergency replacement, so the event changes the management roster more than the underlying business plan. Bottom line: This is a real executive transition, but not a finance-system disruption. The internal promotion and planned handoff make the business impact look contained, while the reason for Prasad’s departure remains limited to pursuing external opportunities.

What to watch next

Raju Prasad’s transition through November 30, 2026

Original filing on SEC EDGAR

CRISPR Therapeutics CFO change brings internal successor, not a clean break | CRSP Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.